International Conference on Viral Hepatitis 2012
The International Conference on Viral Hepatitis 2012 was jointly sponsored by the Mount Sinai School of Medicine and the International Association of Physicians in AIDS Care (IAPAC), in association with the St. Stephen’s AIDS Trust.
Presentations delivered at the International Conference on Viral Hepatitis 2012 will be posted below as they become available. Please check back frequently as this page will be updated throughout the conference. The conference organizers request that any use of these presentations should include citations to both their presenting authors and relevant conference information (e.g., International Conference on Viral Hepatitis 2012, March 26-27, 2012, New York).
MONDAY, March 26, 2012
KEYNOTE ADDRESS – Are HIV and Other Chronic Disease Models Applicable to Viral Hepatitis?
Roy M. Gulick, MD, Weill Cornell Medical College, New York, NY
PLENARY 1 – HBV Management in 2012… Where Are We Heading?
Calvin Q. Pan, MD, Mount Sinai School of Medicine, New York, NY
PLENARY 2 – The DAAs in our Quiver…and Those We Might Have Soon
Douglas T. Dieterich, MD, Mount Sinai School of Medicine, New York, NY
DEBATE SESSION 1 – Should We Treat HCV with PEG-IFN + DAAs or Wait for IFN-Free Options?
Moderator: Mark R. Nelson, MD, Chelsea & Westminster Hospital, London, England
Panelist 1: Kosh Agarwal, MD, King’s College Hospital, London, England Presentation
Panelist 2: Marina Nuñez, MD, PhD, Wake Forest University, Winston-Salem, NC Presentation
DEBATE SESSION 2 – Liver Biopsy in Viral Hepatitis – Minimal or Major?
Moderator: Douglas T. Dieterich, MD, Mount Sinai School of Medicine, New York, NY
Panelist 1: M. Isabel Fiel, MD, Mount Sinai School of Medicine, New York, NY
Panelist 2: Scott L. Friedman, MD, Mount Sinai School of Medicine, New York, NY
PLENARY 3 – PK and Drug Interactions in the New HCV Clinical Management SOC
David J. Back, PhD, University of Liverpool, Liverpool, England
PLENARY 4 – Non-Cirrhotic Portal Hypertension
Vincent Soriano, MD, PhD, Hospital Carlos III, Madrid, Spain
PLENARY 5 – Hepatitis D and E Clinical Management
Pablo Barreiro, MD, Hospital Carlos III, Madrid, Spain
PLENARY 6 – The Aging Liver in HIV
Marie-Louise C. Vachon, MD, Centre Hospitalier Universitaire de Québec, Québec City, Canada
<!–
AASLD/AGA SATELLITE SYMPOSIUM
–>
TUESDAY, March 27, 2012
PLENARY 7 – Adherence in the Age of HCV Antivirals: Lessons from HIV Adherence Interventions
Robert Gross, MD, MSCE, University of Pennsylvania, Pittsburgh, PA
PLENARY 8 – Resistance to HCV Direct-Acting Antivirals
Mark Sulkowski, MD, Johns Hopkins University, Baltimore, MD
PLENARY 9 – Liver Transplant in HIV-Positive Patients
Thomas D. Schiano, MD, Mount Sinai School of Medicine, New York, NY
CASE STUDIES SESSION 1 – Treatment of Chronic Hepatitis
Moderator: Douglas T. Dieterich, MD, Mount Sinai School of Medicine, New York, NY
Case Study 1: Valérie Martel-Laferrière, MD, Centre Hospitalier Universitaire de Québec, Québec City, Canada
Case Study 2: Massimo Puoti, MD, University of Brescia, Milano, IT Presentation
CASE STUDIES SESSION 2 – Treatment of Acute Hepatitis
Moderator: Mark R. Nelson, MD, Chelsea & Westminster Hospital, London, England
Case Study 1: Daniel S. Fierer, MD, Mount Sinai School of Medicine, New York, NY
Case Study 2: Marina Nuñez, MD, PhD, Wake Forest University, Winston-Salem, NC
Case Study 3: Padmasayee Papineni, MD, Chelsea & Westminster Hospital, London, England
PLENARY 10 – International Epidemic of Sexually Transmitted HCV – Update and Controversies
Daniel S. Fierer, MD, Mount Sinai School of Medicine, New York, NY
PLENARY 11 – What do Data in Viral Hepatitis Monoinfection Mean in Relation to Coinfection?
Kosh Agarwal, MD, King’s College Hospital, London, England
PLENARY 12 – Health Workforce Bottleneck – Expanding the Universe of Viral Hepatitis Treaters
Ronald O. Valdiserri, MD, MPH, US Department of Health and Human Services, Washington DC
INVITED PANEL – What is the Future of Viral Hepatitis?
Moderator: Douglas T. Dieterich, MD
Rapporteur: Mark R. Nelson, MD, Mount Sinai School of Medicine, New York, NY
Panelist 1: Kosh Agarwal, MD, King’s College Hospital, London, England
Panelist 2: Massimo Puoti, MD, University of Brescia, Milano, IT Presentation
Panelist 3: Vincent Soriano, MD, PhD, Hospital Carlos III, Madrid, Spain Presentation
Panelist 4: Mark Sulkowski, MD, Johns Hopkins University, Baltimore, MD
ORAL ABSTRACT PRESENTATIONS
79331 – Treatment with the Second-Generation HCV Protease Inhibitor BI201335 Results in High and Consistent SVR Rates – Results from SILEN-C1 in HCV Genotype-1 Treatment-Naïve Patients across Different Baseline Factors
Tarik Asselah presenting
79317 – Sustained Viral Response and Boceprevir Resistance Following Combination Treatment with Boceprevir plus Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Prior Relapsers and Non-Responders
John Howe presenting
79333 – Treatment for 12 or 24 Weeks with BI201335 Combined with Peg-Interferon Alfa-2a and Ribavirin (PR) in Treatment-Naïve Patients with Chronic Genotype-1 HCV Infection: Results of the SILEN-C3 Trial
Douglas T. Dieterich presenting
79340 – MK-5172, a Next Generation HCV NS3/4A Protease Inhibitor is Active against Common Resistance-Associated Variants (RAVs) and Exhibits Cross-Genotype Activity
Richard Barnard presenting
79381 – Effectiveness of Telaprevir in HIV/HCV-Coinfected Patients
Valérie Martel-Laferrière presenting
79383 – Boceprevir for the Treatment of Chronic Hepatitis C and HIV Coinfection
Amena Ahmed presenting
79352 – Interleukin-28B Haplotypes Based on Four Different Single Nucleotide Polymorphisms (SNPs) and Prediction of Sustained Virological Response to PegIFN-a/RBV Therapy in HIV/HCV-Coinfected Patients
Norma Rallón presenting
79357 – Low Risk of Liver Toxicity of the Most Recently Approved Antiretroviral Agents in HIV-Infected Patients but Increased in Hepatitis C Coinfection
Pablo Barreiro presenting
79341 – Frequencies of Resistance-Associated Amino Acid Variants (RAVs) Detected by 454-Sequencing during Combination Treatment with Boceprevir plus Pegintron (Peginterferon Alfa-2b)/Ribavirin/
Richard Barnard presenting
79329 – Changes in Levels of Interleukin-8 in the Serum of Patients with Acute and Chronic Hepatitis B a Predictive Marker of Response to IFN-Therapy
Staffan Sylvan presenting
79332 – Hepatitis C Virus (HCV) Testing and Diagnosis Rates in the Commercially Insured and Medicare Populations in the United States
Camilla Graham presenting
79353 – National Trends and Health Disparities of Hepatitis B and Hepatitis C Viral Infections in the Ambulatory Care
Rajesh Krishnamoorthi presenting
78776 – Sustained Virological Response to Hepatitis C Therapy is Associated with Regression of Liver Fibrosis in HIV/HCV-Coinfected Patients
Pablo Barreiro presenting
78794 – Tritherapy in Patients with Viral Cirrhosis C of Genotype 4: First Results of 2011
André-Jean Remy presenting
79351 – Impact of Natural Variability at the HCV NS3 Protease, NS5B Polymerase, and NS5A Genes on Response to Direct-Acting Antiviral (DAA) Agents
Eva Poveda presenting
79345 – Profile of Patients and Early Virological Response and Tolerance to Hepatitis C Virus NS3/4A Protease Inhibitors in a Reference Clinic in Spain
Pablo Barreiro presenting
<!–
Click here to receive an email notice regarding next year’s International Conference on Viral Hepatitis.
–>
2012 Conference Program and Abstracts
Click below to download the complete 2012 Program in PDF format.
Requires free Acrobat Reader Plugin Software
